1
|
Shammas NW, Purushottam B, Shammas WJ, Christensen L, Shammas G, Weakley D, Jones-Miller S. Jetstream Atherectomy Followed by Paclitaxel-Coated Balloons versus Balloon Angioplasty Followed by Paclitaxel-Coated Balloons: Twelve-Month Exploratory Results of the Prospective Randomized JET-RANGER Study. Vasc Health Risk Manag 2022; 18:603-615. [PMID: 35942041 PMCID: PMC9356602 DOI: 10.2147/vhrm.s371177] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2022] [Accepted: 07/07/2022] [Indexed: 11/23/2022] Open
Affiliation(s)
- Nicolas W Shammas
- Midwest Cardiovascular Research Foundation, Davenport, IA, USA
- Correspondence: Nicolas W Shammas, Research Director, Midwest Cardiovascular Research Foundation, 630 East 4th Street, Suite A, Davenport, IA, USA, Email
| | - Bhaskar Purushottam
- Regional Health CR, Cardiovascular Medicine, Monument Health, Rapid City, SD, USA
| | - W John Shammas
- Midwest Cardiovascular Research Foundation, Davenport, IA, USA
| | | | - Gail Shammas
- Midwest Cardiovascular Research Foundation, Davenport, IA, USA
| | - Desyree Weakley
- Midwest Cardiovascular Research Foundation, Davenport, IA, USA
| | | | | |
Collapse
|
2
|
Rimamskep SG, Favour M, Demilade SA, Charles AC, Olaseni BM, Bob-Manuel T. Peripheral Artery Disease: A comprehensive updated review. Curr Probl Cardiol 2021; 47:101082. [PMID: 34906615 DOI: 10.1016/j.cpcardiol.2021.101082] [Citation(s) in RCA: 20] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2021] [Accepted: 12/07/2021] [Indexed: 11/03/2022]
Abstract
Peripheral arterial disease is estimated to affect more than 200 million people worldwide. Although more than 50% of those affected are asymptomatic, it accounts for 3-4% of amputations and a crude five-year death rate of 82.4 deaths per 1000 patient-years when adjusted for duration of follow-up. Additionally, peripheral artery disease is often an indicator of obstructive atherosclerotic disease involvement of cerebral and coronary vessels, consequently increasing the risk of stroke, cardiovascular death, and myocardial infarction in these patient populations. The management of peripheral arterial disease includes conservative therapies, pharmacological treatments, interventional and surgical revascularization of blood vessels. Percutaneous transluminal angioplasty with balloons and stents has improved clinical outcomes compared to medical treatment alone. Despite these advances, the prevalence of peripheral arterial disease remains high. This review article aims to provide focused, up-to-date information on the clinical course, diagnosis, medical and interventional approach of the management of peripheral artery disease.
Collapse
Affiliation(s)
| | - Markson Favour
- Department of Internal Medicine, Lincoln Medical Centre NY, USA
| | | | | | | | | |
Collapse
|
3
|
Gupta R, Malgor RD, Siada S, Lai S, Al-Musawi M, Malgor EA, Jacobs DL. Critical Appraisal of the Contemporary Use of Atherectomy to Treat Femoral-Popliteal Atherosclerotic Disease. J Vasc Surg 2021; 75:697-708.e9. [PMID: 34303802 DOI: 10.1016/j.jvs.2021.07.106] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2020] [Accepted: 07/06/2021] [Indexed: 12/12/2022]
Abstract
OBJECTIVE Atherectomy has become increasingly used as an endovascular treatment of lower extremity atherosclerotic disease in the United States. Concerns and controversies about its indication and outcomes exist. The goal of this systematic review and meta-analysis was to investigate the outcomes and complications related to atherectomy to treat femoropopliteal atherosclerotic disease. METHODS A systematic review following the recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement was performed. Four major scientific repositories, MEDLINE, EMBASE, The Cochrane Library, and Thompson Web of Sciences were queried from their inception to April 5, 2020. Data was reviewed and entered in a dedicated dataset by the investigators. Outcomes included patency rates, clinical and hemodynamic improvement, and morbidity and mortality associated with atherectomy interventions. RESULTS Twenty-four studies encompassing 1900 patients met inclusion criteria for this study. 74.3% of patients presented with Rutherford class (RC) 1-3 and 25.7% presented with RC class 4-6. 1445 patients underwent atherectomy, and 455 patients were treated without atherectomy. Atherectomy patients underwent directional atherectomy (DA, n = 851), rotational atherectomy (RA, n = 851), laser atherectomy (LA, n = 201), and orbital atherectomy (OA, n = 78). The majority of patients additionally received adjunct treatments which were variable across studies and included a combination of stenting, balloon angioplasty (BA), or drug coated balloon (DCB) angioplasty. Technical success was achieved in 92.3% of cases. Distal embolization, vessel perforation, and dissection occurred in 3.4%, 1.9%, and 4% of cases respectively. Initial patency was 95.4% and at 12-month median follow up primary patency was 72.6%. ABI improved from pre-operative mean of 0.6 to post-operative mean of 0.84. Incidence of major amputation and mortality over the follow up period was 2.2% and 3.4% respectively. CONCLUSIONS This review of the published data suggests that femoropopliteal atherectomy can be completed safely while modestly improving ABIs and maintaining one-year patency in nearly three out of four patients; however, this is based on heterogeneous studies that skew generalizable conclusions about atherectomy's efficacy. Atherectomy places a high cost burden on the healthcare system and is utilized in the United States at a higher rate than in other countries. Our review of the literature does not demonstrate clear atherectomy superiority to alternatives that would warrant pervasive and increasing use of this costly technology. Future work should focus on developing high quality randomized controlled trials to determine specific patient and lesion characteristics in which atherectomy can add value.
Collapse
Affiliation(s)
- Ryan Gupta
- General Surgery resident, Department of Surgery, University of Colorado, Anschutz medical center, Aurora, CO
| | - Rafael D Malgor
- Associate Professor, Division of Vascular and Endovascular Surgery, University of Colorado, Anschutz medical center, Aurora, CO.
| | - Sammy Siada
- Vascular Surgery Fellow, Division of Vascular and Endovascular Surgery, University of Colorado, Anschutz medical center, Aurora, CO
| | - Samuel Lai
- General Surgery resident, Department of Surgery, University of Colorado, Anschutz medical center, Aurora, CO
| | - Mohammed Al-Musawi
- Research Associate, Division of Vascular and Endovascular Surgery, University of Colorado, Anschutz medical center, Aurora, CO
| | - Emily A Malgor
- Assistant Professor, Division of Vascular and Endovascular Surgery, University of Colorado, Anschutz medical center, Aurora, CO
| | - Donald L Jacobs
- Chief, Division of Vascular and Endovascular Surgery, University of Colorado, Anschutz medical center, Aurora, CO
| |
Collapse
|
4
|
Czihal M, Findik Z, Bernau C, Seidensticker M, Ricke J, Hoffmann U, Treitl M, Treitl KM. Embolic Protection in Complex Femoropopliteal Interventions: Safety, Efficacy and Predictors of Filter Macroembolization. Cardiovasc Intervent Radiol 2020; 44:700-708. [PMID: 33280059 PMCID: PMC8060209 DOI: 10.1007/s00270-020-02717-w] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/08/2020] [Accepted: 11/16/2020] [Indexed: 10/26/2022]
Abstract
OBJECTIVES To evaluate the safety and efficacy of a filter embolic protection device (FEPD) in endovascular interventions of the femoropopliteal arteries. METHODS Patients who underwent endovascular interventions of the femoropopliteal arteries between 2008 and 2016 and in whom the SpiderFXTM FEPD was applied were included in this retrospective study. Clinical and angiographic characteristics, filter macroembolization (FME), device-related complications, distal embolization, as well as the early clinical and hemodynamic outcome, were assessed. Potential risk factors for FME were evaluated by multivariate analysis. RESULTS A total of 244 cases were identified (203 patients, claudication 60.4%, critical limb ischaemia 39.6%, mean lesion length 13.2 ± 12.9 cm, complete occlusions in 72.7%). Balloon angioplasty ± stenting (BAP), directional atherectomy ± balloon angioplasty ± stenting (DA) and rotational thrombectomy ± balloon angioplasty ± stenting (RT) were performed in 141, 61 and 42 cases, respectively. FEPD placement and retrieval were successful in all but one case each. Permanent filter-related vessel damage was not observed. The rate of FME was 37.3% (BAP 36.2%, DA 32.8%, RT 47.7%). Risk factors for FME in the BAP- and DA-group were total occlusion, lesion length > 19 cm, visible thrombus and diabetes mellitus. The distal embolization rate despite filter protection was 4.1 % (BAP 4.9%, DA 1.6%, RT 4.8%) and was higher in cases with FME compared with those without FME (8.7% vs. 1.5%, p = 0.02). CONCLUSION The Spider FXTM device is safe and effective in capturing embolic debris during femoropopliteal interventions. A residual risk of peripheral embolization remains. LEVEL OF EVIDENCE III, Cohort study.
Collapse
Affiliation(s)
- Michael Czihal
- Division of Vascular Medicine, Medical Clinic and Policlinic IV, Hospital of the Ludwig-Maximilians-University, Pettenkoferstrasse 8a, 80336, Munich, Germany.
| | - Zeynep Findik
- Division of Vascular Medicine, Medical Clinic and Policlinic IV, Hospital of the Ludwig-Maximilians-University, Pettenkoferstrasse 8a, 80336, Munich, Germany.,Clinic and Policlinic for Radiology, Hospital of the Ludwig-Maximilians-University, Munich, Germany
| | - Christoph Bernau
- Division of Vascular Medicine, Medical Clinic and Policlinic IV, Hospital of the Ludwig-Maximilians-University, Pettenkoferstrasse 8a, 80336, Munich, Germany
| | - Max Seidensticker
- Clinic and Policlinic for Radiology, Hospital of the Ludwig-Maximilians-University, Munich, Germany
| | - Jens Ricke
- Clinic and Policlinic for Radiology, Hospital of the Ludwig-Maximilians-University, Munich, Germany
| | - Ulrich Hoffmann
- Division of Vascular Medicine, Medical Clinic and Policlinic IV, Hospital of the Ludwig-Maximilians-University, Pettenkoferstrasse 8a, 80336, Munich, Germany
| | - Marcus Treitl
- Clinic and Policlinic for Radiology, Hospital of the Ludwig-Maximilians-University, Munich, Germany.,Department of Radiology, Neuroradiology, Interventional Radiology, Berufsgenossenschaftliche Unfallklinik, Murnau, Germany
| | - Karla-Maria Treitl
- Clinic and Policlinic for Radiology, Hospital of the Ludwig-Maximilians-University, Munich, Germany
| |
Collapse
|
5
|
Ochoa Chaar CI, Kim TI, Shebl FM, Dardik A. The Use of Embolic Protection Devices during Lower Extremity Peripheral Vascular Interventions. Ann Vasc Surg 2020; 69:9-16. [DOI: 10.1016/j.avsg.2020.06.014] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2020] [Revised: 05/28/2020] [Accepted: 06/01/2020] [Indexed: 11/28/2022]
|
6
|
Shammas NW, Petruzzi N, Henao S, Armstrong EJ, Shimshak T, Banerjee S, Latif F, Eaves B, Brothers T, Golzar J, Shammas GA, Jones-Miller S, Christensen L, Shammas WJ. JetStream Atherectomy for the Treatment of In-Stent Restenosis of the Femoropopliteal Segment: One-Year Results of the JET-ISR Study. J Endovasc Ther 2020; 28:107-116. [PMID: 32885736 DOI: 10.1177/1526602820951916] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
PURPOSE To report the results of a study evaluating JetStream atherectomy for the treatment of in-stent restenosis (ISR). MATERIALS AND METHODS The JetStream XC atherectomy device, a rotational cutter with aspiration capacity, was evaluated in a prospective, multicenter study (JET-ISR) of 60 patients (mean age 70.2±10.8 years; 40 men) with femoropopliteal ISR (ClinicalTrials.gov identifier NCT02730234). Lesion length was 19.9±13.5 cm; 33 (55%) were chronic total occlusions and 26 (45%) were TransAtlantic Inter-Society Consensus class D. No drug-bearing device was allowed, and stenting was performed only for bailout. Lesion characteristics and stent integrity were evaluated by an independent core laboratory. The primary endpoint was target lesion revascularization (TLR) at 6 months with bailout stenting considered as TLR. Secondary endpoints included TLR (without bailout stenting) and clinical patency (no restenosis or TLR) at 1 year. The Kaplan-Meier method was employed to evaluate time-to-event endpoints; estimates are given with 95% confidence interval (CI). RESULTS Bailout stenting was required in 6 of 60 limbs (10%). There were no stent fractures or deformities after atherectomy + adjunctive angioplasty reported by the core laboratory. Kaplan-Meier estimates of freedom from TLR at 6 months and 1 year were 79.3% (95% CI 68.9% to 89.8%) and 60.7% (95% CI 47.8% to 73.6%), respectively. When bailout stenting at the index procedure was not considered a TLR event, freedom from TLR estimates at 6 months and 1 year were 89.3% (95% CI 81.2% to 97.4%) and 66.8% (95% CI 54.3% to 74.2%), respectively. Clinical patency rates at 6 months and 1 year were 77.5% (31/40) and 51.7% (15/29), respectively. CONCLUSION JetStream atherectomy using the XC device and no drug-eluting devices is feasible, with good clinical patency and 1-year freedom from TLR.
Collapse
Affiliation(s)
| | | | - Steven Henao
- New Mexico Heart Institute, Albuquerque, NM, USA
| | | | - Thomas Shimshak
- Florida Hospital, Heartland Medical Center, Sebring, FL, USA
| | - Subhash Banerjee
- VA North Texas Health Care System, Dallas VA Medical Center, Dallas, TX, USA
| | - Faisal Latif
- US Department of Veterans Affairs, Oklahoma City VA Medical Center, Oklahoma City, OK, USA
| | | | | | - Jaafer Golzar
- Advocate Health and Hospital Corporation, Advocate Christ Medical Center, Oak Lawn, IL, USA
| | - Gail A Shammas
- Midwest Cardiovascular Research Foundation, Davenport, IA, USA
| | | | | | - W John Shammas
- Midwest Cardiovascular Research Foundation, Davenport, IA, USA
| |
Collapse
|
7
|
Giannopoulos S, Armstrong EJ. WIRION™ embolic protection system for carotid artery stenting and lower extremity endovascular intervention. Future Cardiol 2020; 16:527-538. [PMID: 32253940 DOI: 10.2217/fca-2020-0023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
Aim: To summarize all available literature regarding the Wirion™ embolic protection system (EPS) and present examples from our center. Materials & methods: A review of literture was performed about the utilization of Wirion EPS. Results: One study was identified investigating the outcomes of Wirion during carotid artery stenting. The study demonstrated 98.3% procedural success with stroke occurring in only 2.5%. Two single arm studies were identified investigating the efficacy of the Wirion filter during lower extremity endovascular interventions. The reported device success ranged from 95.1 to 97.3%. Conclusion: While carotid artery stenting should always be performed with adjunctive EPS in order to decrease the risk of cerebrovascular accidents, the routine use of EPS in femorpopliteal interventions remains an active area of investigation.
Collapse
Affiliation(s)
- Stefanos Giannopoulos
- Division of Cardiology, Rocky Mountain Regional VA Medical Center, University of Colorado, Denver, CO 80045, USA
| | - Ehrin J Armstrong
- Division of Cardiology, Rocky Mountain Regional VA Medical Center, University of Colorado, Denver, CO 80045, USA
| |
Collapse
|
8
|
Sharis EM, Shammas NW, Shammas GA, Jones-Miller S. WIRION EPS Filter with Jetstream Atherectomy of Femoropopliteal Arterial Disease: A Single Center Experience. CARDIOVASCULAR REVASCULARIZATION MEDICINE 2018; 21:96-99. [PMID: 30503038 DOI: 10.1016/j.carrev.2018.11.014] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2018] [Accepted: 11/13/2018] [Indexed: 11/25/2022]
Abstract
BACKGROUND The WIRION EPS filter was recently approved by the Food and Drug Administration (FDA) to be used in conjunction with all atherectomy devices when treating infrainguinal peripheral arterial disease. The safety of this filter with Jetstream atherectomy (JA) in a real world setting remains unclear. METHODS Consecutive patients from the practice of one operator who underwent JA under WIRION EPS when treating femoropopliteal arteries were enrolled in this retrospective analysis. The primary safety endpoint was the ability of the filter to capture macrodebris with no dissection or thrombosis at the filter site and no filter-related major adverse events. Descriptive analysis on demographics, clinical, procedural and angiographic variables was done using mean ± SD for continuous variables and percentages for categorical variables. RESULTS 37 patients were enrolled in this study between June 2016 and September of 2018 (64.9% males, age 68.7 ± 9.0, BMI 27.7 ± 5.4). TASC II classification of the treated lesions were 51.4% B, 24.3% A, 21.6% C, and 2.7% D. At the filter site, spasm occurred in 1/37 (2.7%), while dissection did not occur (0%). Embolization within the filter was found in 51.4% of patients: 14/37 (37.8%) macro debris and 5/35 (13.5%) micro debris. Clinically significant embolization distal to the filter that required treatment with more than a simple aspiration was 1/37 (2.7%). CONCLUSION WIRION EPS filter use with Jetstream atherectomy was safe and was associated with a low rate of significant distal embolization that required more than a simple aspiration to treat.
Collapse
Affiliation(s)
- Elizabeth M Sharis
- Midwest Cardiovascular Research Foundation, Davenport, IA, United States of America
| | - Nicolas W Shammas
- Midwest Cardiovascular Research Foundation, Davenport, IA, United States of America.
| | - Gail A Shammas
- Midwest Cardiovascular Research Foundation, Davenport, IA, United States of America
| | - Susan Jones-Miller
- Midwest Cardiovascular Research Foundation, Davenport, IA, United States of America
| |
Collapse
|
9
|
Performance Goal Criteria for Device Evaluation in Lower Extremity Peripheral Vascular Intervention and the Need for Standardized Data Structure. JACC Cardiovasc Interv 2018; 11:2004-2006. [DOI: 10.1016/j.jcin.2018.06.036] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/13/2018] [Accepted: 06/19/2018] [Indexed: 11/20/2022]
|